Committee for Orphan Medicinal Products public summary of positive opinion for orphan designation of pazopanib hydrochloride for the treatment of renal cell carcinoma.

On 29 Jun 2006, orphan designation (EU/3/06/382) was granted by the European Commission to GlaxoSmithKline Research & Development Ltd, UK, for pazopanib hydrochloride for the treatment of renal cell carcinoma. The sponsorship was transferred to Glaxo Group Ltd, UK, in December 2008. On 20 Feb 2009, the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) published a public summary of positive opinion for orphan designation of pazopanib hydrochloride for the treatment of renal cell carcinoma. There are questions & answers covering: What is renal cell carcinoma?, What is the estimated number of patients affected by the condition?, What treatments are …